TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ANIP

ANI Pharmaceuticals, Inc. - Common Stock

NASDAQ
$70.20
▼ $2.37 (-3.3%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 19 Nov 2026
H $87.19L $67.14-11.8%
$87.19$83.18$79.17$75.16$71.15$67.14$70.19
RSI (14)
Intraday · 15-minSell-15RSI 39SidewaysMACD Bearishfor day-trading context — not advice

Technical signal

Sell-35
RSI (14)46
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$67.14
Resistance
$76.00
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-18 → 2026-11-19

Strategy return
-6.8%
Buy & hold
-9.8%
Trades
5
Win rate
40%

$100,000.00 invested would be worth $93,203.80 (-6.8%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About ANI Pharmaceuticals, Inc.· Drug Manufacturers - Specialty & Generic

source: yahoo

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
970
Headquarters
Princeton, United States
www.anipharmaceuticals.com ↗

Fundamentals

source: yahoo
Market cap
$1.56B
P/E
13.9
P/B
2.3
EPS
$4.93
Div yield
0.0%
Profit margin
11.2%
ROE
20.4%
Debt / Equity
0.97
Beta
0.47
52-week range
$67.14 – $87.76
52-week low · $67.1415% of rangehigh · $87.76

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive4↑ · 0↓ · 4–
  • ANI Pharmaceuticals to Present at Upcoming December Investor Conference— Neutral
    GlobeNewswire · 19 Nov 2026
  • Did Earnings Beat Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?▲ Positive
    Simply Wall St. · 12 Nov 2026
  • ANIP Q3 2026 deep dive: rare disease expansion and Cortrophin bottlenecks shape outlook▲ Positive
    StockStory · 10 Nov 2026
  • Is ANI Pharmaceuticals (ANIP) A Bargain After Its $560m Deal?
— Neutral
Simply Wall St. · 08 Nov 2026
  • ANI Pharmaceuticals (ANIP) Offers $560 Million For Rare Disease Expansion▲ Positive
    Simply Wall St. · 08 Nov 2026
  • Should ANI Pharmaceuticals (ANIP) Look Undervalued As Results Land And Revenue Guidance Narrows?— Neutral
    Simply Wall St. · 08 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.